Millennium Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-844,073
| Closed | -$111M | – | 6503 |
|
|
2025
Q1 | $111M | Buy |
844,073
+323,247
| +62% | +$40.3M | 0.06% | 309 |
|
|
2024
Q4 | $43.5M | Buy |
520,826
+21,526
| +4% | +$1.77M | 0.02% | 878 |
|
|
2024
Q3 | $36.5M | Sell |
499,300
-389,802
| -44% | -$29.3M | 0.02% | 1044 |
|
|
2024
Q2 | $60.9M | Buy |
889,102
+606,358
| +214% | +$42.1M | 0.03% | 681 |
|
|
2024
Q1 | $19.6M | Sell |
282,744
-90,761
| -24% | -$6.24M | 0.01% | 1578 |
|
|
2023
Q4 | $26.8M | Sell |
373,505
-90,426
| -19% | -$5.2M | 0.01% | 1294 |
|
|
2023
Q3 | $24.2M | Sell |
463,931
-168,983
| -27% | -$9.84M | 0.01% | 1265 |
|
|
2023
Q2 | $40.1M | Buy |
632,914
+134,526
| +27% | +$8.38M | 0.02% | 885 |
|
|
2023
Q1 | $27M | Sell |
498,388
-898,232
| -64% | -$43.4M | 0.02% | 1116 |
|
|
2022
Q4 | $73.9M | Sell |
1,396,620
-444,429
| -24% | -$22.3M | 0.04% | 529 |
|
|
2022
Q3 | $85.7M | Buy |
1,841,049
+803,772
| +77% | +$42M | 0.05% | 411 |
|
|
2022
Q2 | $59.2M | Buy |
1,037,277
+311,808
| +43% | +$17.7M | 0.04% | 546 |
|
|
2022
Q1 | $44.4M | Buy |
725,469
+92,312
| +15% | +$4.79M | 0.02% | 763 |
|
|
2021
Q4 | $33.1M | Sell |
633,157
-103,994
| -14% | -$4.37M | 0.02% | 1022 |
|
|
2021
Q3 | $27.5M | Buy |
737,151
+94,173
| +15% | +$3.27M | 0.02% | 1050 |
|
|
2021
Q2 | $26.2M | Sell |
642,978
-155,074
| -19% | -$5.73M | 0.02% | 982 |
|
|
2021
Q1 | $27.1M | Sell |
798,052
-796,101
| -50% | -$27.6M | 0.02% | 865 |
|
|
2020
Q4 | $50.7M | Sell |
1,594,153
-401,743
| -20% | -$10.6M | 0.04% | 449 |
|
|
2020
Q3 | $51.2K | Buy |
1,995,896
+1,808,241
| +964% | +$41.3M | 0.06% | 301 |
|
|
2020
Q2 | $4.82M | Sell |
187,655
-268,478
| -59% | -$5.43M | 0.01% | 1799 |
|
|
2020
Q1 | $7.01M | Buy |
456,133
+196,279
| +76% | +$4.26M | 0.02% | 1097 |
|
|
2019
Q4 | $8.92M | Sell |
259,854
-977,114
| -79% | -$11.7M | 0.01% | 1471 |
|
|
2019
Q3 | $9.24M | Buy |
1,236,968
+1,101,616
| +814% | +$10.6M | 0.01% | 1333 |
|
|
2019
Q2 | $1.76M | Sell |
135,352
-577,306
| -81% | -$7.4M | ﹤0.01% | 2484 |
|
|
2019
Q1 | $8.68M | Sell |
712,658
-212,847
| -23% | -$2.72M | 0.01% | 1366 |
|
|
2018
Q4 | $10.5M | Buy |
925,505
+381,508
| +70% | +$6.16M | 0.02% | 1099 |
|
|
2018
Q3 | $11.8M | Sell |
543,997
-406,508
| -43% | -$8.5M | 0.01% | 1190 |
|
|
2018
Q2 | $16.8M | Buy |
950,505
+376,537
| +66% | +$7.65M | 0.02% | 968 |
|
|
2018
Q1 | $12.1M | Sell |
573,968
-880,976
| -61% | -$17.2M | 0.02% | 1208 |
|
|
2017
Q4 | $21.1M | Buy |
1,454,944
+71,980
| +5% | +$1.11M | 0.03% | 874 |
|
|
2017
Q3 | $21.8M | Buy |
+1,382,964
| New | +$20.3M | 0.03% | 745 |
|
|
2017
Q2 | – | Sell |
-352,647
| Closed | -$5.73M | – | 3949 |
|
|
2017
Q1 | $5.73M | Sell |
352,647
-133,846
| -28% | -$1.94M | 0.01% | 1375 |
|
|
2016
Q4 | $7.34M | Buy |
486,493
+105,290
| +28% | +$1.49M | 0.02% | 1096 |
|
|
2016
Q3 | $5.81M | Sell |
381,203
-238,734
| -39% | -$9.65M | 0.01% | 1246 |
|
|
2016
Q2 | $24.1M | Sell |
619,937
-614,093
| -50% | -$22.1M | 0.06% | 445 |
|
|
2016
Q1 | $34.3M | Buy |
1,234,030
+285,346
| +30% | +$9.51M | 0.09% | 277 |
|
|
2015
Q4 | $51M | Buy |
948,684
+453,872
| +92% | +$22.9M | 0.11% | 228 |
|
|
2015
Q3 | $19.8M | Buy |
494,812
+1,768
| +0.4% | +$57.7K | 0.04% | 568 |
|
|
2015
Q2 | $15.8M | Buy |
+493,044
| New | +$12.5M | 0.03% | 735 |
|
|
2014
Q3 | – | Sell |
-17,172
| Closed | -$290K | – | 4060 |
|
|
2014
Q2 | $290K | Buy |
17,172
+1,391
| +9% | +$23K | ﹤0.01% | 2893 |
|
|
2014
Q1 | $287K | Buy |
+15,781
| New | +$285K | ﹤0.01% | 2962 |
|
Other funds holding ITCI
KIM
HNB
Millennium Management's ITCI Position: Q2 2025 in Review
Millennium Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 844,073 shares — an estimated $111M sold.
Millennium Management first reported a position in ITCI in Q1 2014 and held it in 41 quarters. The position peaked at $111M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Millennium Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Millennium Management sold 844,073 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $111M.
- Millennium Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 41 quarters.
- Millennium Management's Intra-Cellular Therapies Inc. position peaked at $111M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.